TrialCancer immunology, immunotherapy : CII2017

Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.

Wolfgang Lilleby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.